Histological outcome during long-term lamivudine therapy.

By J. Dienstag, Robert D. Goldin, E. Heathcote, H. Hann, M. Woessner, S. Stephenson, S. Gardner, D. Gray, E. Schiff. Gastroenterology, 2003

762 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/716d7e7d9a8f41cee824a555cff35b92c6ea1925

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Goodman

In Hepatology

1. Z. Goodman

Citations in the corpus

• Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. (2009, background): “Even for patients with established cirrhosis, nucleoside/nucleoside analogues have been shown to potentially revert it [30].”
• Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B (2010, methodology): “A cohort of previously nucleoside-naive, HBeAg-positive CHB patients were treated with lamivudine and were followed for 3 years.(25) In this report, 35 of 65 patients (56%) experienced histological improvement.”